Abstract
The US Department of Defense recently assembled electronic records of outpatient prescriptions dispensed through the Uniformed Services Prescription Database Project (USPDP) going back to 1990. The objectives of this portion of a larger study were: (1) to examine longitudinally the patterns of antihypertensive drug use during the first year of therapy in patients whose initial therapy was with an angiotensin-converting enzyme (ACE) inhibitor or a calcium channel blocker (CCB); (2) to determine continuous and noncontinuous users of antihypertensive drugs; and (3) to estimate the direct medication costs for each pattern of medication use. Filtering criteria for patient and prescription identification were developed, because the USPDP contains no records of confirmatory diagnoses of hypertension. Once data filters were implemented, information for 771 patients was analyzed. An ACE inhibitor was the initial therapy for 328 patients, accounting for 1935 antihypertensive medication prescription fills, and a CCB was the initial therapy for 443 patients, accounting for 2459 fills (including refills). Slightly more than half of the patients (n = 401, 52.0%) were classified as continuous users (> or = 80% medication-possession ratio [sup...Continue Reading
References
Jun 1, 1988·American Journal of Public Health·A L DannenbergW B Kannel
Feb 1, 1984·Annals of Internal Medicine·S A ErakerM H Becker
Jul 1, 1994·Drugs·D A Sica
Jul 29, 1995·BMJ : British Medical Journal·J K JonesA P Fletcher
May 10, 1995·JAMA : the Journal of the American Medical Association·B M PsatyG H Rutan
Jan 1, 1997·Journal of Clinical Epidemiology·J F Steiner, A V Prochazka
Citations
Nov 7, 2002·Current Hypertension Reports·William C Gerth
Nov 4, 2000·Current Hypertension Reports·K A Payne, S Esmonde-White
Oct 17, 2002·Clinical Therapeutics·Robert WeissTimothy Clifford
Sep 16, 1998·Clinical Therapeutics·B S Bloom
May 28, 2005·Journal of Human Hypertension·C BourgaultJ-P Grégoire
Apr 20, 2000·Pharmacotherapy·M LawrenceM J Anderson
Mar 25, 2008·Therapeutics and Clinical Risk Management·Nicola Fitz-SimonJohn Feely
Sep 15, 2004·PharmacoEconomics·Luca Degli Esposti, Giorgia Valpiani
Jan 30, 2002·Clinical Therapeutics·P R ConlinS J Boccuzzi
Jul 31, 2013·Journal of the American Society of Hypertension : JASH·Larissa GrigoryanDavid J Hyman
Jul 26, 2006·Pharmacotherapy·J Alexander ColeAlexander M Walker
Jul 27, 2001·Diabetes Care·S J BoccuzziJ Kim
Dec 7, 2007·Clinical and Experimental Hypertension : CHE·Maria Grazia PrandinClaudio Borghi
Mar 24, 2012·American Journal of Hypertension·Larissa GrigoryanDavid J Hyman
May 23, 2017·Journal of Managed Care & Specialty Pharmacy·Kalyani B Sonawane DeshmukhRichard A Hansen
May 31, 2002·Journal of Human Hypertension·E Degli EspostiM Volpe
Apr 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Krista A Payne, J Jaime Caro
Sep 6, 2007·The American Journal of Geriatric Cardiology·Michael A Weber, Nanette K Wenger
Sep 6, 2007·The American Journal of Geriatric Cardiology·Claudio BorghiEnrico Strocchi
Jun 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Stefania LopatrielloPierfrancesco Ruffo
Nov 5, 2003·Journal of Hypertension·Judith A Whitworth, UNKNOWN World Health Organization, International Society of Hypertension Writing Group
Nov 5, 2003·Journal of Hypertension·Michael A Weber
Oct 26, 2006·Clinical Therapeutics·Patricia A CaetanoSteven G Morgan